Hormone replacement therapy is associated with improved survival in women with advanced heart failure

JoAnn Lindenfeld, Jalal K. Ghali, Heidi J. Krause-Steinrauf, Steven Khan, Kirkwood Adams, Steven Goldman, Mary Ann Peberdy, Clyde Yancy, Surai Thaneemit-Chen, Rhonda L. Larsen, James Young, Brian Lowes, Yves D. Rosenberg

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVES: We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction. BACKGROUND: There are about two million postmenopausal women in the U.S. with HF. However, limited data are available to assess the effects of HRT on survival in this large group of patients. METHODS: A retrospective analysis of women age 50 years and over entered into the Beta-Blocker Evaluation of Survival Trial (BEST) was conducted using Cox regression analysis comparing survival in HRT users and non-users after correcting for baseline variables known to predict survival in women with HF and systolic dysfunction. RESULTS: In 493 women age 50 years and older, HRT was associated with a significant reduction in mortality - 21% mortality in HRT users and 34% in non-users (p = 0.025). Multivariate analysis demonstrated a hazard ratio for mortality of 0.6 (95% confidence interval = 0.36 to 0.97) (p = 0.039) for HRT users. The benefits of HRT were noted only in women with a nonischemic etiology of HF (n = 237). CONCLUSIONS: Hormone replacement therapy is associated with a marked improvement in survival in postmenopausal women with advanced HF. A prospective, randomized trial of HRT should be performed in this large group of patients.

Original languageEnglish (US)
Pages (from-to)1238-1245
Number of pages8
JournalJournal of the American College of Cardiology
Volume42
Issue number7
DOIs
StatePublished - Oct 1 2003

Fingerprint

Hormone Replacement Therapy
Heart Failure
Survival
Systolic Heart Failure
Mortality
Multivariate Analysis
Regression Analysis
Confidence Intervals

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hormone replacement therapy is associated with improved survival in women with advanced heart failure. / Lindenfeld, JoAnn; Ghali, Jalal K.; Krause-Steinrauf, Heidi J.; Khan, Steven; Adams, Kirkwood; Goldman, Steven; Peberdy, Mary Ann; Yancy, Clyde; Thaneemit-Chen, Surai; Larsen, Rhonda L.; Young, James; Lowes, Brian; Rosenberg, Yves D.

In: Journal of the American College of Cardiology, Vol. 42, No. 7, 01.10.2003, p. 1238-1245.

Research output: Contribution to journalArticle

Lindenfeld, J, Ghali, JK, Krause-Steinrauf, HJ, Khan, S, Adams, K, Goldman, S, Peberdy, MA, Yancy, C, Thaneemit-Chen, S, Larsen, RL, Young, J, Lowes, B & Rosenberg, YD 2003, 'Hormone replacement therapy is associated with improved survival in women with advanced heart failure', Journal of the American College of Cardiology, vol. 42, no. 7, pp. 1238-1245. https://doi.org/10.1016/S0735-1097(03)00938-0
Lindenfeld, JoAnn ; Ghali, Jalal K. ; Krause-Steinrauf, Heidi J. ; Khan, Steven ; Adams, Kirkwood ; Goldman, Steven ; Peberdy, Mary Ann ; Yancy, Clyde ; Thaneemit-Chen, Surai ; Larsen, Rhonda L. ; Young, James ; Lowes, Brian ; Rosenberg, Yves D. / Hormone replacement therapy is associated with improved survival in women with advanced heart failure. In: Journal of the American College of Cardiology. 2003 ; Vol. 42, No. 7. pp. 1238-1245.
@article{06dbf26ad6a643ce99e2229c5041b17b,
title = "Hormone replacement therapy is associated with improved survival in women with advanced heart failure",
abstract = "OBJECTIVES: We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction. BACKGROUND: There are about two million postmenopausal women in the U.S. with HF. However, limited data are available to assess the effects of HRT on survival in this large group of patients. METHODS: A retrospective analysis of women age 50 years and over entered into the Beta-Blocker Evaluation of Survival Trial (BEST) was conducted using Cox regression analysis comparing survival in HRT users and non-users after correcting for baseline variables known to predict survival in women with HF and systolic dysfunction. RESULTS: In 493 women age 50 years and older, HRT was associated with a significant reduction in mortality - 21{\%} mortality in HRT users and 34{\%} in non-users (p = 0.025). Multivariate analysis demonstrated a hazard ratio for mortality of 0.6 (95{\%} confidence interval = 0.36 to 0.97) (p = 0.039) for HRT users. The benefits of HRT were noted only in women with a nonischemic etiology of HF (n = 237). CONCLUSIONS: Hormone replacement therapy is associated with a marked improvement in survival in postmenopausal women with advanced HF. A prospective, randomized trial of HRT should be performed in this large group of patients.",
author = "JoAnn Lindenfeld and Ghali, {Jalal K.} and Krause-Steinrauf, {Heidi J.} and Steven Khan and Kirkwood Adams and Steven Goldman and Peberdy, {Mary Ann} and Clyde Yancy and Surai Thaneemit-Chen and Larsen, {Rhonda L.} and James Young and Brian Lowes and Rosenberg, {Yves D.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0735-1097(03)00938-0",
language = "English (US)",
volume = "42",
pages = "1238--1245",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Hormone replacement therapy is associated with improved survival in women with advanced heart failure

AU - Lindenfeld, JoAnn

AU - Ghali, Jalal K.

AU - Krause-Steinrauf, Heidi J.

AU - Khan, Steven

AU - Adams, Kirkwood

AU - Goldman, Steven

AU - Peberdy, Mary Ann

AU - Yancy, Clyde

AU - Thaneemit-Chen, Surai

AU - Larsen, Rhonda L.

AU - Young, James

AU - Lowes, Brian

AU - Rosenberg, Yves D.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - OBJECTIVES: We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction. BACKGROUND: There are about two million postmenopausal women in the U.S. with HF. However, limited data are available to assess the effects of HRT on survival in this large group of patients. METHODS: A retrospective analysis of women age 50 years and over entered into the Beta-Blocker Evaluation of Survival Trial (BEST) was conducted using Cox regression analysis comparing survival in HRT users and non-users after correcting for baseline variables known to predict survival in women with HF and systolic dysfunction. RESULTS: In 493 women age 50 years and older, HRT was associated with a significant reduction in mortality - 21% mortality in HRT users and 34% in non-users (p = 0.025). Multivariate analysis demonstrated a hazard ratio for mortality of 0.6 (95% confidence interval = 0.36 to 0.97) (p = 0.039) for HRT users. The benefits of HRT were noted only in women with a nonischemic etiology of HF (n = 237). CONCLUSIONS: Hormone replacement therapy is associated with a marked improvement in survival in postmenopausal women with advanced HF. A prospective, randomized trial of HRT should be performed in this large group of patients.

AB - OBJECTIVES: We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction. BACKGROUND: There are about two million postmenopausal women in the U.S. with HF. However, limited data are available to assess the effects of HRT on survival in this large group of patients. METHODS: A retrospective analysis of women age 50 years and over entered into the Beta-Blocker Evaluation of Survival Trial (BEST) was conducted using Cox regression analysis comparing survival in HRT users and non-users after correcting for baseline variables known to predict survival in women with HF and systolic dysfunction. RESULTS: In 493 women age 50 years and older, HRT was associated with a significant reduction in mortality - 21% mortality in HRT users and 34% in non-users (p = 0.025). Multivariate analysis demonstrated a hazard ratio for mortality of 0.6 (95% confidence interval = 0.36 to 0.97) (p = 0.039) for HRT users. The benefits of HRT were noted only in women with a nonischemic etiology of HF (n = 237). CONCLUSIONS: Hormone replacement therapy is associated with a marked improvement in survival in postmenopausal women with advanced HF. A prospective, randomized trial of HRT should be performed in this large group of patients.

UR - http://www.scopus.com/inward/record.url?scp=10744220461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220461&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(03)00938-0

DO - 10.1016/S0735-1097(03)00938-0

M3 - Article

C2 - 14522488

AN - SCOPUS:10744220461

VL - 42

SP - 1238

EP - 1245

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -